Synagis (MedImmune Inc) en es it fr

Synagis (MedImmune Inc) Brand names, Synagis (MedImmune Inc) Analogs

Synagis (MedImmune Inc) Brand Names Mixture

  • No information avaliable

Synagis (MedImmune Inc) Chemical_Formula

No information avaliable

Synagis (MedImmune Inc) RX_link

http://www.rxlist.com/cgi/generic2/palivizumab.htm

Synagis (MedImmune Inc) fda sheet

Synagis (MedImmune Inc) msds (material safety sheet)

Synagis (MedImmune Inc) Synthesis Reference

sequence listed in Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24.

Synagis (MedImmune Inc) Molecular Weight

No information avaliable

Synagis (MedImmune Inc) Melting Point

61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

Synagis (MedImmune Inc) H2O Solubility

No information avaliable

Synagis (MedImmune Inc) State

Liquid

Synagis (MedImmune Inc) LogP

No information avaliable

Synagis (MedImmune Inc) Dosage Forms

Powder for solution

Synagis (MedImmune Inc) Indication

For treatment of respiratory diseases casued by respiratory syncytial virus

Synagis (MedImmune Inc) Pharmacology

Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.

Synagis (MedImmune Inc) Absorption

No information avaliable

Synagis (MedImmune Inc) side effects and Toxicity

No information avaliable

Synagis (MedImmune Inc) Patient Information

No information avaliable

Synagis (MedImmune Inc) Organisms Affected

No information avaliable